Total Gastrectomy for Gastric Cancer: An Analysis of Postoperative and Long-Term Outcomes Through Time: Results of 413 Consecutive Cases in a Single Cancer Center

Annals of Surgical Oncology

Volumn 22, Issue 3, 2015, Pages 750-757

  da Costa, Wilson Luiz ^a   Coimbra, Felipe J F ^a   Ribeiro, Héber S C ^a   Diniz, Alessandro L ^a   de Godoy, André Luís ^a   de Farias, Igor Correia ^a   Begnami, Maria Dirlei F S ^a   Soares, Fernando Augusto ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; METHYLENE BLUE;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; ENTERIC FEEDING; ERYTHROCYTE; ESOPHAGOJEJUNAL ANASTOMOSIS FISTULA; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INTESTINE FISTULA; INTRACAVITARY ABSCESS; JEJUNOSTOMY; LINITIS PLASTICA; LONG TERM CARE; LUNG INFECTION; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIMODALITY CANCER THERAPY; NASOGASTRIC TUBE; NUTRITIONAL SUPPORT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS FISTULA; PANCREAS RESECTION; PNEUMONIA; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; ROUX Y ANASTOMOSIS; SPLENECTOMY; STOMACH ADENOCARCINOMA; SURGICAL MORTALITY; TIME; TOTAL STOMACH RESECTION; VERY ELDERLY; WEIGHT REDUCTION; ADENOCARCINOMA; CANCER STAGING; CLINICAL TRIAL; GASTRECTOMY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RISK FACTOR; STOMACH NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84925519730     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4212-6     Document Type: Article

References (26)

1. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.
2. McCullouch P, Ward J, Tekkis PP, ASCOT Group of Surgeons, British Oesophago-Gastric Cancer Group. Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study. BMJ. 2003;327:1192–7.
3. Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy. Japan Clinical Oncology Group study 9501. J Clin Oncol. 2005;22:2767–73.
4. Meyer L, Meyer F, Dralle H, et al. Insufficiency risk or esophagojejunal anastomosis after total abdominal gastrectomy for gastric carcinoma. Langenbecks Arch Surg. 2005;390:510–6.
5. American Society of Anesthesiologists. ASA physical status classification system. Available from: http://www.asahq.org/. Accessed 30 Aug 2014.
6. Dindo D, Demartines N, Clavien PA. Classification of surgical complications. Ann Surg. 2004;240:205–13.
7. Sobin LH, Gospodarowicz MK, Wittekind C. International Union Against Cancer (UICC) TNM classification of malignant tumours. 7th edition. New York: Wiley-Liss; 2010, pp. 73–76.
8. Altini M, Carretta E, Morgagni P, et al. Is a clear benefit in survival enough to modify patient access to the surgery service? A retrospective analysis in a cohort of gastric cancer patients. Gastric Cancer. 2014. doi: 10.1007/s10120-014-0346-2.
9. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer. 1999;79:1522–30.
10. Bonnenkamp JJ, Hermans J, Sasako M, et al; Dutch Gastric Cancer Group. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908–14.
11. Songun I, Putter H, Kranenbarg EMK, Sasako M, van de Velde CJH. Surgical treatment of gastric cancer: 15-year follow-up results of the randomized nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.
12. Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer. 2002;5:1–5.
13. Bartlett EK, Roses RE, Ketz RR, Drebin JA, Fraker DL, Karakousis GC. Morbidity and mortality after total gastrectomy for gastric malignancy using the American College of Surgeons National Surgical Quality Improvement Program database. Surgery. 2014;156:298–304.
14. Watanabe M, Miyata H, Gotoh M, et al. Total gastrectomy risk model: data from 20,011 Japanese patients in a nationwide internet-based database. Ann Surg. 2014;00:1–6.
15. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453–62.
16. Weitz J, Jaques DP, Brennan M, Karpeh M. Association of splenectomy with postoperative complications in patients with proximal gastric and gastroesophageal junction cancer. Ann Surg Oncol. 2004;11:682–9.
17. Martin RC 2nd, Jaques DP, Brennan MF, Karpeh M. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. Ann Surg. 2002;236:159–65.
18. Hartgrink H, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374:477–90.
19. Coimbra FJF, Costa WL Jr, Montagnini AL. The interaction between N-category and N-ratio as a new tool to improve lymph node metastasis staging in gastric cancer: results of a single cancer center in Brazil. Eur J Surg Oncol. 2011;37:47–54.
20. Papenfuss W, Kukar M, Oxenberg DO, et al. Morbidity and mortality associated with gastrectomy for gastric cancer. Ann Surg Oncol. 2014;21:3008–14.
21. Pacelli F, Papa V, Rosa F, et al. Four hundred consecutive total gastrectomies for gastric cancer: a single-institution experience. Arch Surg. 2008;143:769–75.
22. Mahar AL, Coburn NG, Singh S, Law C, Helyer LK. A systematic review of surgery for non-curative gastric cancer. Gastric Cancer. 2012;15 Suppl 1:25–37.
23. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.
24. Maconi G, Manes G, Porro GB. Role of symptons in diagnosis and outcome of gastric cancer. World J Gastroenterol. 2008;14:1149–55.
25. Quan J, Zhang R, Liang H, et al. The impact of tumor size on survival of patients with pT4aN0M0 gastric cancer. Am Surg. 2013;79:328–31.
26. Bilci A, Uygun K, Seker M, et al. The effect of tumor size on overall survival in patients with T3 gastric cancer: experience from 3 centers. Onkologie. 2010;33:676–82.